阿奇霉素联合特布他林序贯治疗小儿支原体肺炎的疗效及安全性评价

Efficacy and safety evaluation of azithromycin combined with terbutaline sequential treatment of mycoplasma pneumonia in children

目的:分析阿奇霉素联合特布他林序贯治疗小儿支原体肺炎的疗效及安全性。方法:2019年5月-2020年7月收治支原体肺炎患儿80例,随机分为两组。对照组接受阿奇霉素序贯治疗;观察组接受阿奇霉素联合特布他林序贯治疗。比较两组治疗效果。结果:观察组体温恢复正常时间、咳嗽缓解时间及肺部啰音消失时间均短于对照组,住院时间亦少于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组治疗后超敏C反应蛋白(hs-CRP)及外周白细胞计数(WBC)水平均低于对照组,差异有统计学意义(P<0.05)。结论:阿奇霉素联合特布他林序贯治疗小儿支原体肺炎的临床疗效可观,且安全性较高。

Objective:To analyze the efficacy and safety of azithromycin combined with terbutaline sequential treatment of mycoplasma pneumonia in children.Methods:From May 2019 to July 2020,80 children with mycoplasma pneumonia were selected,they were randomly divided into the two groups.The control group received azithromycin sequential treatment.The observation group received azithromycin combined with terbutaline sequential treatment.We compared the treatment effects of the two groups.Results:The time for body temperature to return to normal,the time for cough relief and the disappearance of pulmonary rales in the observation group were significantly shorter than those in the control group,and the hospital stay was also significantly shorter than that in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of reactions(P>0.05).The levels of high-sensitivity C-reactive protein(hs-CRP)and peripheral white blood cell count(WBC)in the observation group after treatment were significantly lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion:Azithromycin combined with terbutaline sequential treatment of mycoplasma pneumonia in children has considerable clinical efficacy and high safety.